Physician profile
Fereshte Khavari
NPI 1750334827
$4,994.80
in general payments reported to CMS, 2019-2025
24 companies · $791 in 2025
The $791 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $849 · 2021: $697 · 2022: $294 · 2023: $665 · 2024: $852 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,308.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $864.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $464.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $460.93 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $397.51 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $394.55 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.46 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $317.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $240.86 | 2019-2025 | Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $227.09 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $197.08 | 2019-2022 | |
| Pfizer INC. | $186.39 | 2019-2025 | |
| Amarin Pharma, INC. | $180.66 | 2019-2021 | |
| Glaxosmithkline, LLC. | $142.14 | 2019-2024 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $120.15 | 2019-2025 | Zoryve |
| Currax Pharmaceuticals LLC | $72.11 | 2023-2025 | Contrave, Onzetra Xsail, Nexlizet |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $66.35 | 2021-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $66.17 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $63.14 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $61.61 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.03 | 2022 | |
| Exact Sciences Corporation | $32.94 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $32.27 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $21.81 | 2024 | Inspire |
| Eisai INC. | $15.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fereshte Khavari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.